Green Cross Corp Total Assets
Green Cross Corp total assets. Based on the latest financial reports, Green Cross Corp (006280) holds total assets worth ₩3.19 Trillion KRW (≈ $2.16 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Green Cross Corp for the company's overall valuation and market capitalisation.
Total Assets of Green Cross Corp (2003–2024)
Total assets of Green Cross Corp from 2003 to 2024. This chart illustrates how Green Cross Corp's total assets have evolved over time, based on quarterly financial data. See Green Cross Corp share price for real-time trading data and today's change.
Green Cross Corp - Asset Composition Analysis
Green Cross Corp Total Assets Breakdown (December 2024)
Green Cross Corp total assets breakdown as of December 2024. Green Cross Corp's total assets of ₩3.19 Trillion consist of 43.8% current assets and 56.2% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0.8% |
| Accounts Receivable | ₩386.53 Billion | 14.1% |
| Inventory | ₩746.58 Billion | 27.2% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩181.77 Billion | 6.6% |
| Goodwill | ₩125.61 Billion | 4.6% |
Asset Composition Trend (2003–2024)
This chart illustrates how Green Cross Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Green Cross Corp to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Green Cross Corp's current assets represent 43.8% of total assets in 2024, an increase from 0.0% in 2003.
- Cash Position: Cash and equivalents constituted 0.8% of total assets in 2024, down from 3.2% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 4.0% in 2003.
- Asset Diversification: The largest asset category is inventory at 27.2% of total assets.
Green Cross Corp Competitors by Total Assets
Key competitors of Green Cross Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329
|
China | CN¥11.59 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
Green Cross Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.18 | 1.55 | 1.92 |
| Quick Ratio | 0.51 | 0.70 | 1.18 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩223.84 Billion | ₩432.09 Billion | ₩542.64 Billion |
Green Cross Corp - Advanced Valuation Insights
This section examines the relationship between Green Cross Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.15 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 3.8% |
| Total Assets | ₩2.74 Trillion |
| Market Capitalization | $1.04 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Green Cross Corp's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Green Cross Corp's assets grew by 3.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Green Cross Corp (2003–2024)
The table below shows the annual total assets of Green Cross Corp from 2003 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩2.74 Trillion ≈ $1.86 Billion |
+3.80% |
| 2023-12-31 | ₩2.64 Trillion ≈ $1.79 Billion |
+4.66% |
| 2022-12-31 | ₩2.53 Trillion ≈ $1.71 Billion |
+2.57% |
| 2021-12-31 | ₩2.46 Trillion ≈ $1.67 Billion |
+14.44% |
| 2020-12-31 | ₩2.15 Trillion ≈ $1.46 Billion |
+9.80% |
| 2019-12-31 | ₩1.96 Trillion ≈ $1.33 Billion |
+13.69% |
| 2018-12-31 | ₩1.72 Trillion ≈ $1.17 Billion |
+1.16% |
| 2017-12-31 | ₩1.70 Trillion ≈ $1.15 Billion |
+9.86% |
| 2016-12-31 | ₩1.55 Trillion ≈ $1.05 Billion |
+9.57% |
| 2015-12-31 | ₩1.42 Trillion ≈ $959.01 Million |
+6.37% |
| 2014-12-31 | ₩1.33 Trillion ≈ $901.56 Million |
+20.47% |
| 2013-12-31 | ₩1.10 Trillion ≈ $748.34 Million |
+15.70% |
| 2012-12-31 | ₩954.38 Billion ≈ $646.77 Million |
+10.93% |
| 2011-12-31 | ₩860.35 Billion ≈ $583.05 Million |
+16.06% |
| 2010-12-31 | ₩741.30 Billion ≈ $502.37 Million |
+104.40% |
| 2006-12-31 | ₩362.68 Billion ≈ $245.78 Million |
+22.22% |
| 2005-12-31 | ₩296.73 Billion ≈ $201.09 Million |
+18.32% |
| 2004-12-31 | ₩250.79 Billion ≈ $169.96 Million |
+184.80% |
| 2003-12-31 | ₩88.06 Billion ≈ $59.68 Million |
-- |
About Green Cross Corp
GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-… Read more